Kymera Therapeutics
KYMR
173 hedge funds and large institutions have $2B invested in Kymera Therapeutics in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 58 reducing their positions, and 29 closing their positions.
19% more call options, than puts
Call options by funds: $7.84M | Put options by funds: $6.59M
10% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 58
1.46% more ownership
Funds ownership: 110.73% → 112.19% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
4% less funds holding
Funds holding: 180 → 173 (-7)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
31% less capital invested
Capital invested by funds: $2.89B → $2B (-$888M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$47.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$25.1M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$17.9M |
| 4 |
Millennium Management
New York
|
+$14.4M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$20.1M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$15.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.4M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$14.1M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$8.74M |
KYMR Hedge Fund Activity: Q1 2025 in Review
173 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q1 2025, worth a combined $2B — down 31% from $2.89B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of KYMR and 22 opened new positions — a net loss of 7 holders — while 58 trimmed existing stakes and 64 added.
The largest buyer was Avoro Capital Advisors, adding an estimated $47.8M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $20.1M sold.
- 173 institutional investors held Kymera Therapeutics (KYMR) as of Q1 2025, down from 180 in Q4 2024.
- Funds reported $2B of Kymera Therapeutics stock for Q1 2025, down 31% quarter-over-quarter.
- 22 funds opened new Kymera Therapeutics positions in Q1 2025 and 29 closed out, a net change of -7 holders.
- The largest Kymera Therapeutics buyer in Q1 2025 was Avoro Capital Advisors, an estimated $47.8M added.
- The largest Kymera Therapeutics seller in Q1 2025 was Avidity Partners Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q1 2025.